Management and short-term outcomes of neonates born to mothers with active perinatal SARS-CoV-2 infection.

OBJECTIVE: We report here on the management and outcomes of neonates born to mothers with active perinatal SARS-CoV-2 infection. STUDY DESIGN: In this prospective study, eligible neonates were enrolled in a database to track in-hospital outcomes and followed up outpatient periodically till 2 months of age to assess for late onset symptoms of infection. RESULTS: From April 2020 to February 2021, 67 mothers with perinatal SARS-CoV-2 infection and 70 at-risk neonates were included. Two neonates (3%) tested positive for SARS-CoV-2 within 48 h of life but remained asymptomatic during hospitalization and at all follow-up periods. Three infants were reported to have a febrile illness in 2 months follow up period, none of which was attributable to SARS-CoV-2. CONCLUSION: Our data supports the emerging evidence which describes a probable low risk of vertical transmission of SARS-CoV-2. We also demonstrate a low risk of post-natal transmission or late-onset symptomatic infection with SARS-CoV-2.

Comparing maternal substance use and perinatal outcomes before and during the COVID-19 pandemic.

OBJECTIVE: To examine the effect of the COVID-19 pandemic on maternal substance abuse and neonatal outcomes. STUDY DESIGN: Cross-sectional observational study of neonates admitted to the NICU and born to mothers with evidence of substance abuse pre-pandemic compared to during the COVID-19 pandemic. RESULT: We noted a significant increase in fentanyl (12% vs. 0.6%, p < 0.001) and tobacco use (64% vs. 33%, p < 0.001) during the pandemic compared to pre-pandemic, including an increase in fentanyl use among mothers enrolled in opioid maintenance therapy (OMT) during the pandemic (32.3% vs. 1.5%, p < 0.001). There was a significant increase in preterm births (58% vs. 48%, p = 0.022) and lower birth weight (2315 ± 815 vs. 2455 ± 861 g, p = 0.049) during pandemic. CONCLUSION: There was a significant increase in maternal fentanyl use during the pandemic, even with OMT enrollment, with an increase in preterm births and lower birth weights among infants born to mothers with substance use.

Biological and functional evaluation of a novel pyrolytic carbon implant for the treatment of focal osteochondral defects in the medial femoral condyle: assessment in a canine model.

BACKGROUND: Osteochondral defects continue to be a clinical treatment challenge, and when left untreated, may cause pain and functional impairment. Pyrolytic carbon is a unique isotropic biomaterial used in heart valve and small joint replacements due to its excellent wear properties and biocompatibility with bone and articular cartilage. Therefore, a proposed solution is to utilize a focal pyrolytic carbon hemiarthroplasty implant as an alternative resurfacing treatment strategy for isolated cartilage lesions. METHODS: A canine model (n = 9) was used to evaluate the in vivo histologic response and function of a pyrolytic carbon implant replacing a full-thickness osteochondral defect in the medial femoral condyle (MFC) of the knee. The gross appearance and histologic results were compared to an identical cobalt-chromium (Co-Cr) alloy implant placed in a defect in the contralateral MFC and evaluated up to 52 weeks. RESULTS: Extensive bone incorporation to the stem portion was observed for both implant types. The total mean histologic score for the cartilage of the MFC surrounding the pyrolytic carbon implants was significantly improved compared to that of the Co-Cr alloy implants at all evaluation periods (p < 0.05). Histologic grading and gross observations at 52 weeks for pyrolytic carbon implants were similar to those of Co-Cr alloy implants at 24 weeks. At 24 weeks, the mean total histologic score for Co-Cr alloy implants was 11.6 ± 0.7 (0-16 range point; 16 = normal appearance), while at 52 weeks, the mean total score for the pyrolytic carbon implants was 11.7 ± 1.3. Mean total histologic score of opposing medial tibia cartilage for the pyrolytic carbon implants was superior to that of the Co-Cr alloy group at all evaluation periods and significantly improved over the Co-Cr alloy implant group at 24 weeks (p = 0.001) and 52 weeks (p < 0.001). CONCLUSIONS: Use of a pyrolytic carbon implant for reconstruction of a focal cartilage defect demonstrated effective implant fixation and superior in vivo response compared to an identical Co-Cr alloy implant.